Journal of Skin and Stem Cell

Published by: Kowsar

Comparing the Efficiency of Elidel Cream and Elidel Accompanied With Tretinoin Cream in Treatment of Alopecia Areata

Mir Hadi Aziz Jalali 1 , Pezhman Mobasher 2 , * , Ramin Rabbani 1 and Ghazaleh Ahmadi Jazi 1
Authors Information
1 Department of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Journal of Skin and Stem Cell: October 1, 2014, 1 (2); e20108
  • Published Online: October 12, 2014
  • Article Type: Research Article
  • Received: June 15, 2014
  • Revised: September 2, 2014
  • Accepted: September 6, 2014
  • DOI: 10.17795/jssc20108

To Cite: Aziz Jalali M H, Mobasher P, Rabbani R, Ahmadi Jazi G. Comparing the Efficiency of Elidel Cream and Elidel Accompanied With Tretinoin Cream in Treatment of Alopecia Areata, J Skin Stem Cell. 2014 ; 1(2):e20108. doi: 10.17795/jssc20108.

Abstract
Copyright © 2014, Skin and Stem Cell Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnote
References
  • 1. Colombe BW, Lou CD, Price VH. The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis. J Investig Dermatol Symp Proc. 1999; 4(3): 216-9[PubMed]
  • 2. Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol. 1995; 33(5 Pt 1): 757-64[PubMed]
  • 3. Werth VP, White WL, Sanchez MR, Franks AG. Incidence of alopecia areata in lupus erythematosus. Arch Dermatol. 1992; 128(3): 368-71[PubMed]
  • 4. Wang SJ, Shohat T, Vadheim C, Shellow W, Edwards J, Rotter JI. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata (AA). Am J Med Genet. 1994; 51(3): 234-9[DOI][PubMed]
  • 5. Hoffmann R, Happle R. Topical immunotherapy in alopecia areata. What, how, and why? Dermatol Clin. 1996; 14(4): 739-44[PubMed]
  • 6. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998; 39(5 Pt 1): 751-61[PubMed]
  • 7. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001; 137(8): 1063-8[PubMed]
  • 8. El-Zawahry BM, Bassiouny DA, Khella A, Zaki NS. Five-year experience in the treatment of alopecia areata with DPC. J Eur Acad Dermatol Venereol. 2010; 24(3): 264-9[DOI][PubMed]
  • 9. Tang L, Cao L, Sundberg JP, Lui H, Shapiro J. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol. 2004; 13(1): 5-10[DOI][PubMed]
  • 10. Orecchia G, Perfetti L. Alopecia areata and topical sensitizers: allergic response is necessary but irritation is not. Br J Dermatol. 1991; 124(5): 509[PubMed]
  • 11. Strobel R, Rohrborn G. Mutagenic and cell transforming activities of 1-chlor-2,4-dinitrobenzene (DNCB) and squaric-acid-dibutylester (SADBE). Arch Toxicol. 1980; 45(4): 307-14[PubMed]
  • 12. Wilkerson MG, Henkin J, Wilkin JK. Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability. J Am Acad Dermatol. 1984; 11(5 Pt 1): 802-7[PubMed]
  • 13. Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011; 4: 107-15[DOI][PubMed]
  • 14. Das S, Ghorami RC, Chatterjee T, Banerjee G. Comparative assessment of topical steroids, topical tretenoin (0.05%) and dithranol paste in alopecia areata. Indian J Dermatol. 2010; 55(2): 148-9[DOI][PubMed]
  • 15. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol. 2009; 61(4): 592 e1-9[DOI][PubMed]
  • 16. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol. 1987; 123(11): 1491-3[PubMed]
  • 17. Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL. Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol. 1990; 126(6): 756-9[PubMed]
  • 18. Mancuso G, Balducci A, Casadio C, Farina P, Staffa M, Valenti L, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol. 2003; 42(7): 572-5[PubMed]
  • 19. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003; 49(1): 96-8[DOI][PubMed]
  • 20. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica. 1970; 141(3): 193-202[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments